§Why CasetextPricing

Foreign-Trade Zone (FTZ) 29; Authorization of Production Activity; Catalent Pharma Solutions, LLC; (Nonsteroidal Antiandrogen Tablets); Winchester, Kentucky

89 Fed. Reg. 82971 (Oct. 15, 2024)

Foreign-Trade Zone (FTZ) 29; Authorization of Production Activity; Catalent Pharma Solutions, LLC; (Nonsteroidal Antiandrogen Tablets); Winchester, Kentucky

Download PDF
Federal RegisterOct 15, 2024
89 Fed. Reg. 82971 (Oct. 15, 2024)
Document Headings

Document headings vary by document type but may contain the following:

  • the agency or agencies that issued and signed a document
  • the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to
  • the agency docket number / agency internal file number
  • the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions

    • See the Document Drafting Handbook for more details.

    Department of Commerce Foreign-Trade Zones Board
  • [B-34-2024]

    • On June 11, 2024, Catalent Pharma Solutions, LLC, submitted a notification of proposed production activity to the FTZ Board for its facility within FTZ 29, in Winchester, Kentucky.

    The notification was processed in accordance with the regulations of the FTZ Board (15 CFR part 400), including notice in the Federal Register inviting public comment (89 FR 52022, June 21, 2024). On October 9, 2024, the applicant was notified of the FTZ Board's decision that no further review of the activity is warranted at this time. The production activity described in the notification was authorized, subject to the FTZ Act and the FTZ Board's regulations, including section 400.14.

    Dated: October 9, 2024.

    Elizabeth Whiteman,

    Executive Secretary.

    [FR Doc. 2024-23754 Filed 10-11-24; 8:45 am]

    BILLING CODE 3510-DS-P